DETERMINATION OF IN VITRO OUTLET OF ”AMRADIPIN” 4/5 MG TABLETES (GM PHARMACEUTICALS) AND ITS ANALOGUE ”AMLESSA” 4/5 MG TABLETES (KRKA) USING METHOD OF HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY
Arterial hypertension is a major risk factor for the development of vascular diseases of the heart, brain and kidneys for both sexes, different ages and racial groups. According to numerous data, 70% of people with arterial hypertension require combined treatment. One of the most successful combination is a combination of angiotensin-converting enzyme inhibitor - Perindopril and calcium antagonist – Amlodipine . Purpose of investigation was – determination of in vitro outlet of ”amradipin” 4/5 mg tablets produced by the Georgian pharmaceutical company “GMP” and its analogue “amlessa” 4/5 mg tablets produced by the Krka (Slovenia). According to the received results average percent quantity outlet of amlodipine besylate from amradipine is 92,99%, %, from amlessa - 95,49%, inclination in comparison with analogue is -2.62% ( norm ± 5%).2,5 %, average percent quantity outlet of perindopril erbumine from amradipine is 94,26%%, from amlessa - 97,90%, inclination in comparison with analogue is -3.72% ( norm ± 5%).2,5 %. ” amradipin” 4/5 mg tablets containing amlodipine besylate and perindopril erbumine, produced by the Georgian pharmaceutical company ”GMP” are characterized by good outlet quality.
2. Государственная Фармакопея Российской Федерации. XII 2007 .ст 552-553
3. Григорьев Ю.В. Рациональная антигипер- тензивная терапия / / ГВМУ МО РФ, ГИУВ МО РФ: Методические рекомендации. - М., 2000.
4. British Pharmakopoeia. 2013. p2761-2765
5. United States Pharmacopeia 2015